LGND - Ligand Pharmaceuticals President & Chief Operating Trades $1.50M In Company Stock | Benzinga
On May 15, a recent SEC filing unveiled that Matthew E Korenberg, President & Chief Operating at Ligand Pharmaceuticals (NASDAQ:LGND) made an insider sell.
What Happened: Korenberg's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 17,598 shares of Ligand Pharmaceuticals. The total transaction value is $1,495,740.
Tracking the Thursday's morning session, Ligand Pharmaceuticals shares are trading at $85.77, showing a down of 0.0%.
All You Need to Know About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals: A Financial Overview
Revenue Growth: Ligand Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -29.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the ...